Toni K. Choueiri, MD

Toni Choueiri, MD, and Rohit Gosain, MD summarize the implications of the CheckMate 9ER 3-year follow-up data and highlight remaining questions and unmet needs in the RCC landscape.

A brief overview of post-hoc data from the CheckMate 9ER trial examining baseline characteristics and time to subsequent therapy in patients who received at least two years of nivolumab treatment, followed by study conclusions.

Panelists continue to discuss long-term follow-up data from the CheckMate 9ER trial, focusing on treatment-related adverse events seen in patients with ccRCC treated with nivolumab plus cabozantinib.

Two subject matter experts discuss survival and response data from the CheckMate 9ER trial comparing combination nivolumab/cabozantinib to sunitinib in patients with advanced ccRCC.

Drs Choueiri and Gosain review study design, patient demographics, and clinical characteristics from the CheckMate 9ER trial, including prior nephrectomy and PD-L1 status.

Toni Choueiri, MD, and Rohit Gosain, MD share their clinical experience treating patients with clear cell renal cell carcinoma (ccRCC) and provide a short summary of previously reported data from the CheckMate 9ER trial.

At 2022 ASCO GU, Toni K. Choueiri, MD, explained the data seen in the updated results from the KEYNOTE-564 trial for patients with renal cell carcinoma.

At 2022 ASCO GU, Toni K. Choueiri, MD, discussed the CLEAR study and how East Asian patients with renal cell carcinoma derived similar benefit with lenvatinib plus pembrolizumab as the overall trial population.

Choueiri detailed combination treatments with follow-up data presented at the 2021 ASCO Annual Meeting.

Drs Toni Choueiri and Robert J. Motzer highlight various strategies with novel-based therapies being explored to address limitations surrounding the treatment of metastatic renal cell carcinoma.

Considerations regarding the value of using the IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) criteria to risk-stratify patients with metastatic renal cell carcinoma as novel therapies become more widely used.

Recommendations regarding how to use novel combinations such as lenvatinib and everolimus, or lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma.

Treatment-related adverse events to be mindful of when treating patients with metastatic renal cell carcinoma with a TKI/IO regimen, such as lenvatinib and pembrolizumab, in the frontline setting.

Robert J. Motzer, MD, of the Memorial Sloan Kettering Cancer Center, discusses the rationale for studying lenvatinib plus pembrolizumab or everolimus for frontline metastatic renal cell carcinoma treatment and reacts to outcomes of the phase 3 CLEAR study as presented at ASCO GU 2021.

Drs Toni Choueiri and Robert J. Motzer discuss factors that impact their decisions for treatment of metastatic renal cell carcinoma in the first-line setting and highlight their go-to regimens.

Toni Choueiri, MD, of the Dana-Farber Cancer Institute, comments on the impact of emerging data presented on newer, novel combination therapies as upfront treatment for patients with metastatic renal cell carcinoma.

Drs Toni Choueiri and Robert J. Motzer reflect on recent data supporting the use of TKI/I-O combination regimens for frontline treatment of metastatic renal cell carcinoma.

In the phase 3 CheckMate 9ER trial, investigators found that nivolumab plus cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously untreated advanced renal cell carcinoma.

An expert discusses how new data from the phase 3 CheckMate 9ER trial impact therapy choice in previously untreated advanced renal cell carcinoma.